By Drug Target Review –
CAR-T therapy has shown effectiveness in cancer treatment, but relapse often occurs due to limited cell persistence. New strategies aim to improve CAR T-cell durability for longer lasting remission.
immunotherapy has emerged as one of the most promising approaches in the fight against cancer, with chimeric antigen receptor T-cell (CAR-T) therapy marking a significant breakthrough. However, the durability of CAR-T responses remains a major challenge, as many patients eventually relapse. One such promising approach is the development of NKTR-255, an investigational interleukin-15 (IL-15) receptor agonist. NKTR-255 has shown potential in boosting CAR-T therapies, particularly for patients with relapsed or refractory cancer, such as large B-cell lymphoma (LBCL).
